Table 1.
Clinicopathological features of the screening cohort.
| Variable | No. of patients n = 193 |
|---|---|
| Disease | |
| MGUS | 25 (13.0%) |
| sMM | 30 (15.5%) |
| MM | 138 (71.5%) |
| Multiple myeloma patients (n = 138) | |
| R-ISS stage | |
| R-ISS I | 34 (24.6%) |
| R-ISS II | 66 (47.8%) |
| R-ISS III | 28 (20.3%) |
| Missing data | 10 |
| ISS stage | |
| ISS I | 39 (28.3%) |
| ISS II | 42 (30.4%) |
| ISS III | 54 (39.2%) |
| Missing data | 3 |
| Prior sMM/MGUS | |
| Yes | 22 (15.9%) |
| No | 114 (82.6%) |
| Missing data | 2 |
| Gender | |
| Male | 77 (55.8%) |
| Female | 61 (44.2%) |
| Therapy | |
| Bortezomib-based regimens | 121 (87.7%) |
| Lenalidomide-dexamethasone | 11 (8.00%) |
| Other | 2 |
| Missing data | 4 |
| Bone disease | |
| Yes | 90 (65.2%) |
| No | 36 (26.1%) |
| Missing data | 12 |
| HDM/ASCT | |
| Yes | 37 (26.8%) |
| No | 98 (71.0%) |
| Missing data | 3 |
| B2M (mg/L) | |
| Median (min–max) | 4.5 (1.5–36.9) |
| LDH (U/L) | |
| Median (min–max) | 165.5 (71.0–570.0) |
| Marrow plasma cells | |
| <60% | 57 (41.3%) |
| ≥60% | 79 (57.2%) |
| Missing data | 2 |
| Response to 1st line | |
| sCR | 26 (18.8%) |
| CR | 18 (13.1%) |
| VGPR | 46 (33.3%) |
| PR | 31 (22.5%) |
| SD | 8 (5.80%) |
| PD | 2 (1.50%) |
| Missing data | 7 |
| Disease monitoring | |
| Follow-up patients | 133 |
| Relapse | 32 (24.1%) |
| Death/alive | 29 (21.8%) |
| Progression/progression-free survival | 48 (36.0%)/85 (64.0%) |
| Excluded from follow-up | 5 |
HDM/ASCT high-dose melphalan therapy with autologous stem cell transplantation, sCR stringent complete response, CR complete response, VGPR very good partial response, PR partial response, SD stable disease, PD progressed disease.